About Tamino Bio
Tamino Bio is a biotechnology platform company focused on disease-relevant protein regulation, targeted protein modulation, and translational validation.
Our mission is to translate biological signaling into mechanism-based therapeutics that address the underlying drivers of disease.
Founded by scientists with complementary expertise across post-translational modification biology, proteomics, translational models, therapeutic discovery, and disease biology spanning renal, oncologic, cardiovascular, metabolic, fibrotic, and neurodegenerative disorders, Tamino Bio is developing a platform to identify, validate, and therapeutically modulate disease-relevant biological control points.
Platform Foundation
Tamino Bio integrates disease biology, post-translational modification science, multi-omics, biomarker discovery, and therapeutic strategy to identify and modulate disease-relevant biological control points.
Biology
O-GlcNAc / OGT / OGA Biology
O-GlcNAc signaling and OGT/OGA biology provide a foundation for understanding dynamic protein regulation, cellular state, and disease mechanisms.
Multi-Omics
Translational Multi-Omics
Proteomic, phosphoproteomic, metabolomic, lipidomic, transcriptomic (RNA-seq), post-translational modification, and biomarker profiling support mechanism-focused discovery and translational validation.
Therapeutic Focus
Disease-Focused Translation
Initial therapeutic focus is kidney disease, with platform expansion across metabolic, fibrotic, oncologic, cardiovascular, neurodegenerative, and other chronic diseases.
Our Team
Tamino Bio’s founding team brings complementary expertise spanning post-translational modification biology, proteomics, kidney disease biology, translational models, therapeutic discovery, biomarker science, and systems biology. Together, the team is advancing a platform that integrates biological signaling, multi-omics, and therapeutic development to address complex human disease.
Stephen A. Whelan, PhD
Co-Founder
Proteomics, translational biomarkers, PTM-regulated signaling, mass spectrometry, and systems biology.
LinkedIn · Google Scholar · ORCID
Chad Slawson, PhD
Co-Founder
O-GlcNAc biology, post-translational signaling, kidney disease mechanisms, and neurodegeneration biology.
LinkedIn · Google Scholar · ORCID · KUMC Faculty Profile
Pamela Tran, PhD
Co-Founder
Kidney disease biology, translational models, therapeutic validation, and therapeutic delivery strategy.
LinkedIn · Google Scholar · ORCID · KUMC Faculty Profile
Advisors & Collaborators
Strategic Network
Tamino Bio is assembling a strategic network of scientific, translational, computational, clinical, and biotechnology leaders to support platform development and therapeutic translation.